Inclisiran: a new generation of lipid-lowering siRNA therapeutic
Atherosclerotic heart disease (AHD) is a major cause of morbidity and mortality worldwide. Lowering low-density lipoprotein cholesterol (LDL-C) levels is a key strategy to prevent and treat AHD. Inclisiran is a novel siRNA drug that targets proprotein convertase subtilisin/kexin type 9 (PCSK9) gene...
Saved in:
Main Authors: | Yanzhen Zhang (Author), Huaigang Chen (Author), Lang Hong (Author), Hong Wang (Author), Bin Li (Author), Mengyin Zhang (Author), Jiamei Li (Author), Liu Yang (Author), Fan Liu (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tirzepatide's innovative applications in the management of type 2 diabetes and its future prospects in cardiovascular health
by: Jingqi Yang, et al.
Published: (2024) -
Advances in Lipid Nanoparticles for siRNA Delivery
by: Sam Chen, et al.
Published: (2013) -
siRNA targeting ANGPTL3 stands in the spotlight for lipid-lowering therapy
by: Bo Hu, et al.
Published: (2023) -
Effect of the amount of cationic lipid used to complex siRNA on the cytotoxicity and proinflammatory activity of siRNA-solid lipid nanoparticles
by: Mahmoud S. Hanafy, et al.
Published: (2023) -
Profiling patent compounds in lipid nanoparticle formulations of siRNA
by: Yunfeng Han, et al.
Published: (2024)